Christina Coughlin
Directeur Général chez AVACTA GROUP PLC
Postes actifs de Christina Coughlin
Sociétés | Poste | Début | Fin |
---|---|---|---|
AVACTA GROUP PLC | Directeur/Membre du Conseil | 21/03/2022 | - |
Directeur Général | 01/05/2024 | - | |
Directeur Technique/Scientifique/R&D | 01/02/2024 | 01/05/2024 |
Historique de carrière de Christina Coughlin
Anciens postes connus de Christina Coughlin
Sociétés | Poste | Début | Fin |
---|---|---|---|
Cytoimmune Therapeutics, Inc.
Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | Directeur/Membre du Conseil | 10/11/2021 | 18/07/2023 |
Directeur Général | 10/11/2021 | 18/07/2023 | |
RUBIUS THERAPEUTICS | Directeur Technique/Scientifique/R&D | 06/01/2020 | 12/11/2021 |
Tmunity Therapeutics, Inc.
Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | Directeur Technique/Scientifique/R&D | 01/07/2018 | 01/11/2019 |
IMMUNOCORE HOLDINGS PLC | Directeur Technique/Scientifique/R&D | 01/04/2015 | 01/07/2018 |
Formation de Christina Coughlin
Temple University (Pennsylvania) | Undergraduate Degree |
University of Pennsylvania | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 6 |
Royaume-Uni | 3 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 4 |
Director/Board Member | 2 |
Chief Executive Officer | 2 |
Sectorielle
Health Technology | 4 |
Consumer Services | 3 |
Commercial Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
IMMUNOCORE HOLDINGS PLC | Health Technology |
AVACTA GROUP PLC | Commercial Services |
Entreprise privées | 3 |
---|---|
Rubius Therapeutics, Inc.
Rubius Therapeutics, Inc. BiotechnologyHealth Technology Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines. It provides medicine for cancer, autoimmune diseases, hemophilia, infectious and metabolic diseases. The company was founded on April 26, 2013 and is headquartered in Foxboro, MA. | Health Technology |
Tmunity Therapeutics, Inc.
Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | Commercial Services |
Cytoimmune Therapeutics, Inc.
Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | Health Technology |
- Bourse
- Insiders
- Christina Coughlin
- Expérience